Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanothermometry-Enabled Intelligent Laser Tissue Soldering.
Cipolato O, Dosnon L, Rosendorf J, Sarcevic S, Zäch M, Bondi A, Liska V, Schlegel AA, Herrmann IK. Cipolato O, et al. Among authors: liska v. Small Methods. 2023 Nov;7(11):e2300693. doi: 10.1002/smtd.202300693. Epub 2023 Aug 17. Small Methods. 2023. PMID: 37592160
Large-Scale Development of Antibacterial Scaffolds: Gentamicin Sulfate-Loaded Biodegradable Nanofibers for Gastrointestinal Applications.
Klicova M, Mullerova S, Rosendorf J, Klapstova A, Jirkovec R, Erben J, Petrzilkova M, Raabová H, Šatínský D, Melicherikova J, Palek R, Liska V, Horakova J. Klicova M, et al. Among authors: liska v. ACS Omega. 2023 Oct 17;8(43):40823-40835. doi: 10.1021/acsomega.3c05924. eCollection 2023 Oct 31. ACS Omega. 2023. PMID: 37929155 Free PMC article.
miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma.
Mallela VR, Rajtmajerová M, Trailin A, Liška V, Hemminki K, Ambrozkiewicz F. Mallela VR, et al. Among authors: liska v. Noncoding RNA Res. 2023 Oct 24;9(1):24-32. doi: 10.1016/j.ncrna.2023.10.010. eCollection 2024 Mar. Noncoding RNA Res. 2023. PMID: 38075204 Free PMC article. Review.
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate.
Fiala O, Hošek P, Korunková H, Hora M, Kolář J, Šorejs O, Topolčan O, Filipovský J, Liška V, Santoni M, Buti S, Fínek J. Fiala O, et al. Among authors: liska v. Cancer Med. 2024 Jan 2;13(1):e6853. doi: 10.1002/cam4.6853. Online ahead of print. Cancer Med. 2024. PMID: 38164124 Free PMC article.
259 results